Conjugation chemistry for catalytic antibody 38C2
AssigneeUniversity of Florida Research Foundation, Inc.
InventorsChristoph Rader, Dobeen Hwang
Life of this patent
Estimating the term…
Abstract
The present invention provides modified catalytic antibody 38C2 with arylation of the reactive lysine residue (Lys99). The Lys99 residue is arylated with a heteroaryl methyl sulfonyl compound such as methylsulfone phenyl oxadiazole (MS-PODA). The invention also provides antibody conjugated agents (e.g., antibody drug conjugates) that contain an agent moiety that is site-specifically conjugated to 38C2 via a methyl sulfonyl compound. Further provided in the invention are methods of making the antibody conjugated agents and therapeutic applications of the antibody conjugated agents.
Claims18
A catalytic antibody comprising a heavy chain variable domain of SEQ ID NO:4 and a light chain variable domain of SEQ ID NO:3 wherein residue Lys99 of the heavy chain variable domain is heteroarylated.
An antibody-agent conjugate, comprising a catalytic antibody comprising a heavy chain variable domain of SEQ ID NO:4 and a light chain variable domain of SEQ ID NO:3 wherein residue Lys99 of the heavy chain variable domain is heteroarylated and an agent moiety, wherein the agent moiety is conjugated to the heteroarylated Lys99 of the heavy chain variable domain.
Dependencies are inferred from the claim text.